1/15
06:25 pm
abt
Rep. Julia Letlow Discloses Over 200 Stock Trades After Deadline As Ban Debate Grows In Congress [Forbes]
Low
Report
Rep. Julia Letlow Discloses Over 200 Stock Trades After Deadline As Ban Debate Grows In Congress [Forbes]
1/15
05:24 pm
abt
Abbott Laboratories (NYSE:ABT) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $157.00 to $152.00. They now have a "buy" rating on the stock.
Low
Report
Abbott Laboratories (NYSE:ABT) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $157.00 to $152.00. They now have a "buy" rating on the stock.
1/13
07:07 pm
abt
AI Optical Coherence Tomography Market Opportunities to 2029 & 2034 by Type, Technology, Application and Region [Yahoo! Finance]
Low
Report
AI Optical Coherence Tomography Market Opportunities to 2029 & 2034 by Type, Technology, Application and Region [Yahoo! Finance]
1/13
01:36 pm
abt
Why Abbott Laboratories (ABT) Story Is Shifting With Exact Sciences Deal Talk And Legal Wins [Yahoo! Finance]
Low
Report
Why Abbott Laboratories (ABT) Story Is Shifting With Exact Sciences Deal Talk And Legal Wins [Yahoo! Finance]
1/13
10:46 am
abt
PainTEQ Announces Appointment of Lalit Venkatesan, PhD as Senior Vice President of Clinical Research [Yahoo! Finance]
Low
Report
PainTEQ Announces Appointment of Lalit Venkatesan, PhD as Senior Vice President of Clinical Research [Yahoo! Finance]
1/13
07:21 am
abt
Innovative Health Receives 50th FDA Clearance to Reprocess Medical Devices [Yahoo! Finance]
Neutral
Report
Innovative Health Receives 50th FDA Clearance to Reprocess Medical Devices [Yahoo! Finance]
1/13
06:21 am
abt
Abbott Laboratories (NYSE:ABT) is favoured by institutional owners who hold 80% of the company [Yahoo! Finance]
Low
Report
Abbott Laboratories (NYSE:ABT) is favoured by institutional owners who hold 80% of the company [Yahoo! Finance]
1/12
12:53 pm
abt
Can your toothbrush really detect diabetes? FDA scrutiny grows for health-tracking gadgets [Los Angeles Times (CA)]
Low
Report
Can your toothbrush really detect diabetes? FDA scrutiny grows for health-tracking gadgets [Los Angeles Times (CA)]
1/12
09:41 am
abt
Global Pain Management Devices Market to Reach USD 5,835.8 Million by 2029 | MarketsandMarkets™ [Yahoo! Finance]
Low
Report
Global Pain Management Devices Market to Reach USD 5,835.8 Million by 2029 | MarketsandMarkets™ [Yahoo! Finance]
1/9
02:25 pm
abt
Abbott Laboratories (NYSE:ABT) had its price target raised by analysts at Sanford C. Bernstein from $150.00 to $154.00. They now have an "outperform" rating on the stock.
Low
Report
Abbott Laboratories (NYSE:ABT) had its price target raised by analysts at Sanford C. Bernstein from $150.00 to $154.00. They now have an "outperform" rating on the stock.
1/9
12:37 am
abt
Assessing Abbott Laboratories (ABT) Valuation After Libre Assist Expands Its Digital Diabetes Offering [Yahoo! Finance]
Low
Report
Assessing Abbott Laboratories (ABT) Valuation After Libre Assist Expands Its Digital Diabetes Offering [Yahoo! Finance]
1/7
05:26 am
abt
3 Healthcare Stocks with Exciting Potential [Yahoo! Finance]
Low
Report
3 Healthcare Stocks with Exciting Potential [Yahoo! Finance]
1/6
09:27 am
abt
Abbott Laboratories (NYSE:ABT) had its price target raised by analysts at Evercore ISI from $142.00 to $144.00. They now have an "outperform" rating on the stock.
Low
Report
Abbott Laboratories (NYSE:ABT) had its price target raised by analysts at Evercore ISI from $142.00 to $144.00. They now have an "outperform" rating on the stock.
1/6
08:55 am
abt
Should Abbott's AI-Powered Libre Assist Shift Its Diabetes Platform Strategy Narrative for ABT Investors? [Yahoo! Finance]
Low
Report
Should Abbott's AI-Powered Libre Assist Shift Its Diabetes Platform Strategy Narrative for ABT Investors? [Yahoo! Finance]
1/5
04:30 pm
abt
Abbott hosts conference call for fourth-quarter earnings
Low
Report
Abbott hosts conference call for fourth-quarter earnings
1/5
10:02 am
abt
Abbott Laboratories (NYSE:ABT) had its price target raised by analysts at Barclays PLC from $162.00 to $169.00. They now have an "overweight" rating on the stock.
Low
Report
Abbott Laboratories (NYSE:ABT) had its price target raised by analysts at Barclays PLC from $162.00 to $169.00. They now have an "overweight" rating on the stock.
1/5
09:30 am
abt
Abbott's new Libre Assist app feature tackles a top need for people living with diabetes: in-the-moment food decisions [Yahoo! Finance]
Low
Report
Abbott's new Libre Assist app feature tackles a top need for people living with diabetes: in-the-moment food decisions [Yahoo! Finance]
1/5
09:05 am
abt
Abbott's new Libre Assist app feature tackles a top need for people living with diabetes: in-the-moment food decisions
Low
Report
Abbott's new Libre Assist app feature tackles a top need for people living with diabetes: in-the-moment food decisions
1/5
08:52 am
abt
Hologic Trading Near 52-Week High: How Should You Play the Stock? [Yahoo! Finance]
Low
Report
Hologic Trading Near 52-Week High: How Should You Play the Stock? [Yahoo! Finance]
1/2
12:50 am
abt
With EPS Growth And More, Abbott Laboratories (NYSE:ABT) Makes An Interesting Case [Yahoo! Finance]
Low
Report
With EPS Growth And More, Abbott Laboratories (NYSE:ABT) Makes An Interesting Case [Yahoo! Finance]
1/2
12:50 am
abt
Abbott Laboratories (ABT): Buy, Sell, or Hold Post Q3 Earnings? [Yahoo! Finance]
Low
Report
Abbott Laboratories (ABT): Buy, Sell, or Hold Post Q3 Earnings? [Yahoo! Finance]
1/1
05:12 am
abt
Abbott (ABT) Wins FDA Approval for Volt PFA System in AFib Treatment [Yahoo! Finance]
Low
Report
Abbott (ABT) Wins FDA Approval for Volt PFA System in AFib Treatment [Yahoo! Finance]
12/31
07:03 pm
abt
AbbVie (ABBV): Buy, Sell, or Hold Post Q3 Earnings? [Yahoo! Finance]
Low
Report
AbbVie (ABBV): Buy, Sell, or Hold Post Q3 Earnings? [Yahoo! Finance]
12/30
04:09 pm
abt
Abbott Laboratories (NYSE:ABT) had its "buy (b-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Abbott Laboratories (NYSE:ABT) had its "buy (b-)" rating reaffirmed by analysts at
Weiss Ratings.
12/27
09:22 am
abt
Is Weakness In Abbott Laboratories (NYSE:ABT) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects? [Yahoo! Finance]
Low
Report
Is Weakness In Abbott Laboratories (NYSE:ABT) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects? [Yahoo! Finance]